STOCK TITAN

Cedar Holdings (EKSO) reports 210,000-share, 5.89% stake via Schedule 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Ekso Bionics Holdings, Inc. Schedule 13G filing discloses that Cedar Holdings Mgmt LLC beneficially owns 210,000 shares of Common Stock, representing 5.89% of the class based on February 20, 2026 outstanding shares of 3,563,381. The filing states Cedar has shared voting and dispositive power over the shares and that Keith Kosow may be deemed to beneficially own those shares by virtue of his role; Mr. Kosow does not directly own the Shares. The ownership percentages are tied to the issuer's Form 10-K disclosure of shares outstanding as of February 20, 2026.

Positive

  • None.

Negative

  • None.

Insights

Schedules a passive 5.89% position via Cedar; control is shared, not sole.

The filing shows Cedar Holdings Mgmt LLC holds 210,000 shares with shared voting and dispositive power, which creates a measurable but not controlling stake given the 5.89% ownership level based on February 20, 2026 share count.

Dependencies include the accuracy of the Form 10-K share count and the continued classification as a passive investor; subsequent amendments or sales by Cedar or related entities would change the public ownership picture.

Filing follows Rule 13d procedures and attributes indirect ownership to an associated officer.

The Schedule 13G is signed jointly and references a Joint Filing Agreement; it attributes beneficial ownership to Cedar and treats Keith Kosow as potentially deemed beneficial under Rule 13d-3.

Material compliance points include the cover-page voting/dispositive breakdown and the incorporated Form 10-K share count; any future change in intent or ownership would require amendment to reporting status.






282644400

(CUSIP Number)
02/17/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Statement on Schedule 13G (this ''Schedule 13G''), such shares and percentage are based on 3,563,381 shares of common stock, par value $0.001 per share, of the issuer (the ''Common Stock'') outstanding as of February 20, 2026, as disclosed in the issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on February 23, 2026 (the ''Form 10-K'').


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 3,563,381 shares of Common Stock outstanding as of February 20, 2026, as disclosed in the Form 10-K.


SCHEDULE 13G



Kosow Keith
Signature:/s/ Keith Kosow
Name/Title:Individual
Date:03/19/2026
Cedar Holdings Mgmt LLC
Signature:/s/ Keith Kosow
Name/Title:Authorized Signatory
Date:03/19/2026

Comments accompanying signature: See Exhibit 1 filed herewith.

FAQ

How many Ekso Bionics (EKSO) shares does Cedar Holdings report owning?

Cedar Holdings reports beneficial ownership of 210,000 shares. The filing states this equals 5.89% of the class based on 3,563,381 shares outstanding as of February 20, 2026, per the issuer's Form 10-K disclosure.

Does Keith Kosow directly own the shares reported in the Schedule 13G?

No; the filing states Mr. Kosow does not directly own the Shares. He may be deemed to beneficially own them under Rule 13d-3 because he can exercise voting/dispositive power through Cedar.

What voting and dispositive powers are disclosed for the reported shares?

The filing shows shared voting power and shared dispositive power of 210,000 shares. Neither Cedar nor Mr. Kosow is listed with sole voting or sole dispositive power for those shares in the cover-page data.

On what share count is the 5.89% ownership percentage based?

The percentage is based on 3,563,381 shares outstanding as of February 20, 2026, referencing the issuer's Annual Report on Form 10-K filed on February 23, 2026, per the Schedule 13G language.
Ekso Bionics

NASDAQ:EKSO

View EKSO Stock Overview

EKSO Rankings

EKSO Latest News

EKSO Latest SEC Filings

EKSO Stock Data

38.09M
2.66M
Medical Instruments & Supplies
General Industrial Machinery & Equipment, Nec
Link
United States
SAN RAFAEL